Entrada Therapeutics
is a Massachusetts-based biotechnology company that researches and develops novel therapeutics for the treatment of neuromuscular diseases... Read moreEntrada Therapeutics
is a Massachusetts-based biotechnology company that researches and develops novel therapeutics for the treatment of neuromuscular diseases... Read more
News
Aug 05, 2026
Marketscreener
Entrada Therapeutics: Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
Jun 03, 2026
GlobalNewswire
Press Release: Entrada Therapeutics : INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Jun 02, 2026
GlobalNewswire
Press Release: Entrada Therapeutics : Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
May 18, 2026
Benzinga
Entrada Therapeutics: TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
May 18, 2026
Benzinga
Entrada Therapeutics: TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
May 11, 2026
GlobalNewswire
Press Release: Entrada Therapeutics : Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
May 09, 2026
Nasdaq
Entrada Therapeutics: Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
May 08, 2026
Clinical Trials Arena
Entrada Therapeutics: Entrada's stock drops as DMD drug's efficacy falls short
May 07, 2026
Marketscreener
Entrada Therapeutics: Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
May 07, 2026
BioSpace
Entrada Therapeutics: Entrada crashes as Duchenne therapy comes in 'below expectations' in early study
Entrada Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10